Invalid Symbol

Stock Research for GEVA

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


GEVA Stock Chart & Research Data

The GEVA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GEVA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GEVA Due diligence Resources & Stock Charts

The GEVA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GEVA Detailed Price Forecast - CNN Money CNN View GEVA Detailed Summary - Google Finance
Yahoo View GEVA Detailed Summary - Yahoo! Finance Zacks View GEVA Stock Research & Analysis -

Stock Analysis

TradeIdeas View GEVA Trends & Analysis - Trade-Ideas Barrons View GEVA Major Holders - Barrons
NASDAQ View GEVA Call Transcripts - NASDAQ Seeking View GEVA Breaking News & Analysis - Seeking Alpha
Spotlight View GEVA Annual Report - OTC Report View GEVA OTC Short Report -
TradeKing View GEVA Fundamentals - TradeKing Charts View GEVA SEC Filings - Bar Chart
WSJ View Historical Prices for GEVA - The WSJ Morningstar View Performance/Total Return for GEVA - Morningstar
MarketWatch View the Analyst Estimates for GEVA - MarketWatch CNBC View the Earnings History for GEVA - CNBC
StockMarketWatch View the GEVA Earnings - StockMarketWatch MacroAxis View GEVA Buy or Sell Recommendations - MacroAxis
Bullish View the GEVA Bullish Patterns - American Bulls Short Pains View GEVA Short Pain Metrics -

Social Media Mentions

StockTwits View GEVA Stock Mentions - StockTwits PennyStocks View GEVA Stock Mentions - PennyStockTweets
Twitter View GEVA Stock Mentions - Twitter Invest Hub View GEVA Investment Forum News - Investor Hub
Yahoo View GEVA Stock Mentions - Yahoo! Message Board Seeking Alpha View GEVA Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GEVA - Insider Cow View Insider Transactions for GEVA - Insider Cow
CNBC View GEVA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GEVA - OTC Markets
Yahoo View Insider Transactions for GEVA - Yahoo! Finance NASDAQ View Institutional Holdings for GEVA - NASDAQ

Stock Charts

FinViz View GEVA Stock Insight & Charts - StockCharts View GEVA Investment Charts -
BarChart View GEVA Stock Overview & Charts - BarChart Trading View View GEVA User Generated Charts - Trading View

Latest Financial News for GEVA

Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs
Posted on Friday March 17, 2017

Everytime Donald Trump tweets about drug prices, biotech stocks take it on the chin. Bruce Pile believes these episodes are giving informed investors good entry points for some of the best names in biotech.

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Despite no drugs on market, Lexington biotech fetches $8b
Boston Globe - May 6, 2015
... transactions of the year and raising fresh questions about whether such blockbuster buyouts are justified. Synageva BioPharma Corp., a seven-year-old company developing treatments for rare diseases, has kept such a low profile that many industry ...
Alexion to Buy Synageva BioPharma in $8.4 Billion Deal - New York Times
Alexion to bolster rare disease offering with $8.4 billion deal - Reuters

Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer
PR Newswire (press release) - Sep 22, 2014
LEXINGTON, Mass., Sept. 22, 2014 /PRNewswire/ -- Synageva BioPharma Corp. ("Synageva") (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating ...

Synageva Has Eliminated Major Risks To Its Business
Seeking Alpha - Jul 2, 2013
We last covered Synageva BioPharma (NASDAQ:GEVA) in early January, arguing that the company faced fundamental risks that made its valuation a concern moving forward.

Synageva BioPharma and Trimeris Announce Merger Agreement
Business Wire (press release) - Jun 13, 2011
LEXINGTON, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), and Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris”), announced today that ...

Enter a stock symbol to view the stock details.